Alemtuzumab Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Alemtuzumab was first introduced in the US for the treatment of B-cell chronic
lymphocytic leukemia (CLL) in patients who have been treated with alkylating agents and
have failed fludarabine therapy. Alemtuzumab is a humanized monoclonal antibody of the
IgG1 isotype specific for the glycoprotein CD52 expressed on the cell surface of over 95%
of normal and malignant B and T lymphocytes and monocytes. It was genetically
engineered by adding six hypervariable regions from the heavy-chain and light-chain
variable domains of an IgG2a rat monoclonal antibody onto a human IgG1 immunoglobulin
molecule. The exact mechanism of action of alemtuzumab is unknown but the antibody
probably causes the lysis of lymphocytes via complement fixation and antibody-dependent
cytotoxicity. In a phase III clinical trial with 93 fiudarabine-resistant CLL patients, treatment
with alemtuzumab gave a positive response in 31 patients with 2 complete remissions and
29 partial remissions. This study demonstrated a higher response rate in patients having
malignancy confined to the blood and bone marrow. Alemtuzumab does not seem to
penetrate well into solid tissues and it was found to be concentrated in the blood which
seems to correlate with the fact that it appears to be inefficient against tumor cells from
lymph nodes and extranodal masses. The half-life of the antibody ranged between 23 and
30 hours. Premedication with acetaminophen and diphenhydramine is effective in reducing
infusion-related reactions such as fevers, rigors, rash, nausea or hypotension. The most
significant adverse effect is lymphopenia resulting in increased risk of opportunistic
infections. As a consequence, prophylactic treatment with antibiotics is recommended for
patients under alemtuzumab therapy.
Verwenden
Antineoplastic (monoclonal antibody).
Allgemeine Beschreibung
Alemtuzumab (Campath) is humanized MAb (Campath-1H)that is directed against the 21- to 28-kDa cell surface glycoproteinCD52. CD52 is expressed on the surface of normaland malignant B and T lymphocytes, NK cells, monocytes,macrophages, and tissues of the male reproductive system.The Campath-1H antibody is an IgG1 κ form with humanizedvariable and constant regions and CDRs from a ratMAb, Campath-1G.
Alemtuzumab is indicated for the treatment of B-cellchronic lymphocytic leukemia in patients who have beentreated with alkylating agents and who have failed on thistherapy. Alemtuzumab binds to CD52, a nonmodulating antigen that is present on the surface of essentially all B andT lymphocytes; most monocytes, macrophages, and NKcells, and a subpopulation of granulocytes. The proposedmechanism of action is antibody-dependent lysis ofleukemic cells following cell surface binding.
Alemtuzumab Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
